- Home
- NXTC vs GDHG Comparison
NXTC vs GDHG Comparison
Compare NXTC & GDHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- GDHG
- Stock Information
- Founded
- NXTC 2015
- GDHG 2008
- Country
- NXTC United States
- GDHG China
- Employees
- NXTC N/A
- GDHG N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- GDHG Services-Misc. Amusement & Recreation
- Sector
- NXTC Health Care
- GDHG Consumer Discretionary
- Exchange
- NXTC Nasdaq
- GDHG Nasdaq
- Market Cap
- NXTC 9.3M
- GDHG 11.0M
- IPO Year
- NXTC 2019
- GDHG 2023
- Fundamental
- Price
- NXTC $0.43
- GDHG $0.31
- Analyst Decision
- NXTC Strong Buy
- GDHG
- Analyst Count
- NXTC 2
- GDHG 0
- Target Price
- NXTC $3.50
- GDHG N/A
- AVG Volume (30 Days)
- NXTC 259.7K
- GDHG 4.6M
- Earning Date
- NXTC 05-05-2025
- GDHG 04-29-2025
- Dividend Yield
- NXTC N/A
- GDHG N/A
- EPS Growth
- NXTC N/A
- GDHG N/A
- EPS
- NXTC N/A
- GDHG N/A
- Revenue
- NXTC N/A
- GDHG $22,333,251.00
- Revenue This Year
- NXTC N/A
- GDHG N/A
- Revenue Next Year
- NXTC N/A
- GDHG N/A
- P/E Ratio
- NXTC N/A
- GDHG N/A
- Revenue Growth
- NXTC N/A
- GDHG N/A
- 52 Week Low
- NXTC $0.22
- GDHG $0.25
- 52 Week High
- NXTC $1.82
- GDHG $19.00
- Technical
- Relative Strength Index (RSI)
- NXTC 44.58
- GDHG 38.10
- Support Level
- NXTC $0.22
- GDHG $0.26
- Resistance Level
- NXTC $0.44
- GDHG $0.39
- Average True Range (ATR)
- NXTC 0.06
- GDHG 0.07
- MACD
- NXTC 0.02
- GDHG -0.03
- Stochastic Oscillator
- NXTC 86.11
- GDHG 20.92
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About GDHG Golden Heaven Group Holdings Ltd.
Golden Heaven Group Holdings Ltd is an offshore holding company. Through the operating entities in China, It manages and operates six properties consisting of amusement parks, water parks, and complementary recreational facilities. The parks offer a broad selection of exhilarating and recreational experiences, including both thrilling and family-friendly rides, water attractions, gourmet festivals, circus performances, and high-tech facilities. The parks collectively contain nearly 159 rides and attractions. The firm's revenue is generated from selling access to rides and attractions, charging fees for special event rentals, and collecting regular rental payments from commercial tenants.